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Abstract
Background: Previous attempts to measure symptoms in pediatric Eosinophilic Esophagitis (EoE) have not fully
included patients and parents in the item development process. We sought to identify and validate key patient
self-reported and parent proxy-reported outcomes (PROs) specific to EoE.
Methods: We developed methodology for focus and cognitive interviews based on the Food and Drug
Administration (FDA) guidelines for PROs, the validated generic PedsQL™ guidelines, and the consolidated criteria
for reporting qualitative research (COREQ). Both child (ages 8-12 and 13-18) and parent-proxy (ages 2-4, 5-7, 8-12,
and 13-18) interviews were conducted.
Results: We conducted 75 interviews to construct the new instrument. Items were identified and developed from
individual focus interviews, followed by cognitive interviews for face and content validation. Initial domains of symptom
frequency and severity were developed, and open-ended questions were used to generate specific items during the
focus interviews. Once developed, the instrument construct, instructions, timeframe, scoring, and specific items were
systematically reviewed with a separate group of patients and their parents during the cognitive interviews.
Conclusions: To capture the full impact of pediatric EoE, both histologic findings and PROs need to be included
as equally important outcome measures. We have developed the face and content validated Pediatric Eosinophilic
Esophagitis Symptom Score (PEESS™ v2.0). The PEESS™ v2.0 metric is now undergoing multisite national field
testing as the next iterative instrument development phase.
Background
In pediatric eosinophilic esophagitis (EoE) there can be a
wide range of symptoms: from the easily recognizable pre-
sentations of food bolus impaction and dysphagia to the
less obvious feeding disorders and abdominal pain [1].
Most previous efforts to develop a questionnaire to mea-
sure pediatric EoE symptoms have focused on correlations
between non-validated symptom scores and histologic
outcomes, specifically peak esophageal eosinophil counts
[2,3]. To date, there have been few validated instruments
that capture symptoms as patient and parent proxy-
reported outcomes (PROs) developed through patient
focus interviews and cognitive interviews as recommended
by the FDA and specific to pediatric EoE [1,4].
Pentiuk et al. developed the non-validated Pediatric
Eosinophilic Esophagitis Symptom Score (PEESS version
1.0) utilizing expert opinion and focusing on correlations
between symptom scores and histologic outcomes. In
their study, Pentiuk and colleagues demonstrated that sub-
jects with untreated EoE had higher PEESS scores than
treated subjects; however, symptom score and histology
were only weakly correlated [5]. Aceves and colleagues
have also recently developed a symptom score through the
modification of a metric utilized for acid peptic disorders
[3]. However, this non-validated tool was again developed
through expert opinion alone and focused on correlations
to histology. In Aceves’s study, the total symptom score
was higher among patients with EoE and gastroesophageal
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However, only symptoms of dysphagia and anorexia/early
satiety were capable of significantly discriminating EoE
from GERD (P < 0.01). Patients with chief complaints
other than dysphagia and anorexia did not have histology
findings that directly correlated with the results of the
modified symptoms scale.
These prior efforts to develop a symptom score for EoE
depending solely on expert opinion have not fully taken
into account patient perceptions of symptom severity or
response to treatment, which are increasingly important to
improving health outcomes and quality of life [4]. There-
fore, there is a significant need for severity indices to be
developed as patient self-report and parent proxy-reported
outcomes. Well designed and validated PROs have been
increasingly recognized as key outcome measures for the
treatment of chronic disease over the past decade. For
example, the recent pediatric asthma randomized clinical
trial for the medication ciclesonide utilized both patient
symptoms and quality of life (QOL) metrics as key out-
come measures and demonstrated improvements in QOL
and symptoms scores in the treated groups relative to the
placebo controls [6]. The National Institutes of Health
identified PROs as key components in the clinical research
“toolbox” and have launched the Patient Reported Out-
comes Measurement Information System (PROMIS,
http://www.nihpromis.org/default.aspx) in an attempt to
provide healthcare workers and researchers with instru-
ments to objectively measure the disease characteristics
that patients and their families deem critically important
for their day-to-day health [7-14]. It is clear that a pedia-
tric EoE symptom score would provide a valuable new
tool with which to better analyze the outcomes in pedia-
tric EoE that are relevant to families.
As a first phase in the development process of a new
PRO instrument, content validity must be established.
The FDA guidelines on PRO development state that,
“item generation should include input from the target
patient population to establish the items that reflect the
concept of interest and contribute to its evaluation.” To
capture outcomes from the patients’ perspective, in 2009
the FDA recommended that it is important to establish
content validity through patient focus groups/interviews
and cognitive think aloud and cognitive debriefing proto-
cols before evaluating other measurement properties.
Basic PRO validation requires feedback from patients and
their parents early in the instrument development pro-
cess to determine if the instrument’s item content cap-
tures the disease features that pediatric patients and
parents believe are important for the instrument to mea-
sure. Content validity is supported using qualitative
research methodologies to investigate whether the PRO
instrument and its respective items measure the symp-
toms of interest from the patients’ perspective. These
qualitative methods are an essential part of the instru-
ment development process from the beginning of the
process, and subsequently testing other measurement
properties will not replace or rectify problems with elicit-
ing patient and parent-proxy focused outcomes from the
initiation phase [7]. In 2008, Flood and colleagues
described their use of cognitive interviews for a new
pediatric EoE metric (Symptom Questionnaire for Eosi-
nophilic Esophagitis) developed by experts in the EoE
field for patients age 8-17 years of age and caregivers of
EoE patients ages 2-7 years of age [15]. Given that the
metric developed by Flood and colleagues was developed
by expert opinion initially with patient input in a single
cohort only, it may be limited in reflecting the patient
experience.
As the primary objective of this study, we sought to
identify key EoE patient self-reported and parent proxy-
reported symptoms through focus interviews, to develop
an EoE PRO symptom metric, and to review the patient
derived metric though cognitive interviews in a separate
cohort. Content validation of the Pediatric Eosinophilic
Esophagitis Symptoms Severity (PEESS™ v2.0) PRO
metric was supported by this iterative process.
Methods
All study protocols were reviewed and approved by the
Institutional Review board at Cincinnati Children’s Hos-
pital Medical Center (CCHMC). All research described
was compliant with the CCHMC ethical guidelines for
clinical research and the Helsinki Declaration (http://
www.wma.net/e/policy/b3.htm). Informed consent was
obtained from all parents and assent for children ages
8-18 years of age.
FDA guidelines on PRO development, the validated
generic PedsQL™ guidelines, and the consolidated cri-
teria for reporting qualitative research (COREQ) were
used to develop the methodology for content validation
[7,13,16].
Research Team
The research team was composed of experts in the field
of EoE including specialty physicians from the fields of
Allergy and Gastroenterology with advanced training in
clinical research methodologies and two Ph.D. psycholo-
gists with specific expertise in qualitative research and
PRO methodology. The entire team developed interview
guidelines, and specific interviewers were trained in qua-
litative methodology. The research team reviewed tran-
scriptions of the interview audiotapes.
Participants
Participants were identified from local and referral popu-
lations with a clinicopathologic diagnosis of EoE based
on chart review and family interview. All participants had
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were reviewed to identify at least one endoscopy with >=
15 eos/hpf isolated to the esophagus. As it was critical to
assess patients’ and families’ concerns that were specific
to EoE, not those related to other co-morbidities, pedia-
tric patient participants were restricted to those with a
diagnosis of EoE and without other co-morbidities,
including clinical diagnoses of: gastroesophageal reflux
(GERD), inflammatory bowel disease, celiac disease,
psychiatric disorder, and/or therapy with psychiatric/
behavioral medication.
Focus Interviews
The methodologies for focus interviews (also termed con-
cept elicitation interviews) have been described previously
[12,17]. Briefly, our research team developed a script of
semi-structured open-ended questions (Table 1). The con-
tent of the PEESS v1.0 was used only as a general outline
for open-ended patient and parent-proxy questions. Inter-
viewers facilitated the participants’ answers by focusing
discussion on the topics under consideration while being
nondirective and nonevaluative. Interviews lasted approxi-
mately one hour, with age stratification in alignment with
the PedsQL™ guidelines (http://www.pedsql.org), consid-
ered a gold standard for pediatric PRO metrics [12].
All sessions were audio-recorded, transcribed verba-
tim, and analyzed by the research team. Responses were
grouped according to domains of interest, age ranges,
and patient vs. parent proxy groups. Content and
themes were then derived by consensus among the
research team. Disagreements were minor and easily
resolved by further discussion and then consensus was
reached within the group.
Expert Opinion
Items derived from the focus interviews were integrated
into a preliminary draft of the PEESS™ version 2.0. Local
(authors) and national (listed in acknowledgements) EoE
experts in the fields of allergy, gastroenterology, and
psychology then reviewed this draft. To retain the focus of
the PEESS™ v2.0 on patient self-reported and parent
proxy-reported outcomes, experts were allowed only to
discuss general concerns and suggest (not delete) addi-
tional items. This additional information was then
reviewed with a separate cohort of subjects in the cogni-
tive interview phase. This step is a critical distinction from
previous EoE metrics [15].
Cognitive Interviews
Cognitive interviews were designed to elicit information
regarding the clarity and rationale of the directions, indivi-
dual items, domains, and response choices, as well as over-
all comments on the relevance and complexity of the
questionnaire. Participants completed and reviewed the
PEESS™ version 2.0 preliminary draft derived from the
focus interviews and provided feedback utilizing the pre-
viously described respondent debriefing methodology [13].
Briefly, cognitive probes and items generated by focus
interview subjects and national experts were assimilated
into a protocol from the existing methodological literature
by Varni and colleagues (Table 2). An item-by-item sum-
mary of each section of the questionnaire, including
recommendations for modifications, was prepared from
transcribed audiotapes and interviewer notes. Using the
same methodology as described for the focus interviews,
items and content generated were revised. Reading level
was assessed using the Flesch Reading Easiness and the
Flesch-Kincaid Grade Level scores and used to further
revise question language and grammar. A summary of the
content validation methodology is provided in Figure 1.
Results
Basic participant demographics of the focus interview
and cognitive interview cohorts are provided in Table 3.
Focus Interviews Patient Self-Report
A total of 36 participants were interviewed, divided
a m o n gc h i l d r e na g e s8 - 1 2a n d1 3 - 1 8a n dp a r e n t so f
Table 1 Focus interview open-ended questions
Participant Questions
What symptoms do you (does your child) have that you relate to EoE?
Not eating?
Pain in chest?
Burning in chest?
Child (Parent) Trouble swallowing (eating food)?
Vomiting/throwing up?
What is the most frequent symptom? How often does this occur?
What is the worst symptom? How often does this occur?
How often to do you call your (your child’s) doctor?
Because of your (your child’s) symptoms, do you (s/he) have trouble in school? Work? Playing with friends?
What trouble do you (your child) have eating food?
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8-12 and 13-18 year age groups described and discussed
their symptoms related to EoE. Three focus interviews
in the 5-7 year age group were also attempted. However,
children in this younger age group were not able to fully
describe and discuss their symptoms. Therefore, only
parent proxy PRO measures were developed for children
in the 2-4 and 5-7 year old age groups. Children ages 8-
12 and 13-18 were interviewed separately from their
parents. Children in the 8-12 and 13-18 year groups
focused on pain and difficulties with eating food.
Regarding frequency, most children described this as
how “often” a particular symptom was occurring.
Regarding severity, all children described this as how
“bad” a particular symptom was. We were surprised to
find how clearly children could discern the feeling of
nausea from vomiting or abdominal pain. Most children
also accurately described heartburn and regurgitation. In
addition, children frequently described dysphagia as
trouble swallowing or the sensation of food getting
stuck.
Focus Interviews Parent Proxy-Report
Although similar to patient self-reported symptoms,
parent proxy-reported concerns often differed regarding
perceptions of symptom severity. In addition, parents
focused more on amounts of food eaten than children
did. Parents also described issues with frequency and
severity of symptoms as separate from the overall ques-
tion of how much of a problem a particular symptom
was for their child.
Expert Opinion
National EoE experts were particularly helpful regarding
dysphagia and the various ways that patients and par-
ents describe this important symptom. In addition to
items asking about trouble swallowing and feelings of
food getting stuck, items were added regarding needing
to drink liquids to help swallow food and extended time
needed to eat food compared to others. Expert opinions
were added to the PEESS™ v2.0 draft to be reviewed by
the cognitive interview cohort. No items were deleted
based on expert opinion.
Focus Interviews Item and Instrument Draft Development
Thirty-six focus interview transcripts were analyzed.
Content and themes derived by consensus among the
research team are summarized in Table 4. Once devel-
oped, the instrument construct, instructions, timeframe,
scoring, and items were systematically reviewed with a
different group of patients and their parents during the
cognitive interviews.
Cognitive Interview Patient Self-Report
A different cohort of 39 participants divided evenly
a m o n gc h i l d r e na g e s8 - 1 2a n d1 3 - 1 8a n dp a r e n t so f
children ages 2-4, 5-7, 8-12, and 13-18 were interviewed.
Results from the separate cohort of children with EoE in
the 8-12 and 13-18 year groups who participated in the
cognitive interview respondent debriefing are summar-
ized in Table 2. In general, participants thought that the
PEESS™ version 2.0 preliminary draft was much easier
to understand than the PEESS v1.0. In response to
Table 2 Cognitive interview respondent debriefing
Subject Question
Directions How would you make the directions more clear/easy to understand?
What does “in the past month” mean to you?
When you see “the past month”, what days did you include?
Items In your own words, what do you think this question is asking?
What does this question mean to you? What did you think of when answering this question?
Was this question easy to understand? Are there any specific words that are difficult to understand?
How would you change the words to make it more clear?
Was this item hard to answer? If yes, why?
How did you choose your answer?
Domains In your own words, what do you think this group of questions is asking about?
How do you think these items are related?
Are there any questions that do not belong in this group?
Response
Choices
What do you think about the response choices?
How would you make the response choices clearer or easier to understand?
Overall
Assessment
Are there things that we forgot to ask about that you think are important?
Overall thoughts/opinions of the questionnaire?
Anything you would change in the questionnaire as a whole?
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Page 4 of 12PEESS v 1.0 
Physician developed, Unvalidated 
Research team develop list of open-
ended questions 
Focus Interviews: Child 
12 participants total 
Ages 8-12, 13-18 year olds 
Research team reviewed focus 
interview responses 
Focus Interviews: Parent 
24 participants total 
Ages 2-4, 5-7, 8-12, 13-18 year olds 
PEESS™ v 2.0 developed 
Cognitive Interviews: Child 
12 participants total 
Ages 8-12, 13-18 year olds 
Research team reviewed cognitive 
interview responses 
Cognitive Interviews: Parent 
27 participants total 
Ages 2-4, 5-7, 8-12, 13-18 year olds 
PEESS™ v 2.0 validated 
Figure 1 Summary of content validation methodology. Focus interview transcripts of pediatric patients with EoE and their parents were used to
develop the items and domains for the PEESS™ v2.0. Cognitive interviewing was conducted with separate cohorts of pediatric patients and their
parents in the 8-12 and 13-18 year old age groups, while parent proxy-reports were also obtained in the 2-4 year old and 5-7 year old age groups.
Table 3 Demographics of focus interview (FI) and cognitive interview (CI) cohorts
Ages 2-4 Ages 5-7 Ages 8-12 Ages 13-18
Total sample (FI,CI) 13 (6,7) 12 (7,5) 12 (6,6) 13 (7,6)
Male % (FI, CI) 61.5% (3,5) 83% (6,4) 50% (2,4) 61.5% (4,4)
Caucasian % (FI, CI) 77% (5,5) 83% (5,5) 83% (6,4) 92% (7,5)
Non-Hispanic % (FI, CI) 92% (5,7) 100% (7,5) 100% (6,6) 92% (6,6)
Dietary food restrictions for EoE % (FI, CI) 46% (2,4) 75% (5,4) 50% (1,5) 54% (1,6)
Swallowed steroids for EoE % (FI, CI) 46% (4,2) 42% (4,1) 58% (2,5) 38% (4,1)
Food allergies % (FI, CI) 69% (5,4) 75% (5,4) 58% (1,6) 31% (0,4)
Atopic disease % (FI, CI) 61.5% (3,5) 75% (5,4) 42% (2,3) 92% (6,6)
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Item Focus interviews
patient reported symptoms
PEESS™ v2.0 Cognitive interviews:
respondent debriefing
PEESS™ v2.0 content validated
General Patients described how often symptoms
occurred and how bad symptoms as
different concepts
All 36 subjects did not understand
medical terminology in PEESS v1.0
All 39 subjects agreed that the visual analog scale for symptom severity
improved comprehension
Patients preferred items in forms
of questions
Detailed instructions
All 39 subjects preferred PEESS™
v2.0 over PEESS v1.0
Chest Pain 8 reported chest pain. Chest pain, aches or hurt All 39 participants understood the question and preferred to include the
additional descriptive words.
How often do you have chest
pain, ache, or hurt?
How bad is the chest pain, ache,
or hurt?
Heartburn 4 reported heartburn,
1 reported reflux,
4 reported “burning in chest”
Burning in chest, mouth,
or throat (heartburn)
38 out of the 39 participants understand heartburn How often do you have heartburn
(burning in your chest, mouth, or
throat)?
How bad is your heartburn
(burning in your chest, mouth, or
throat)?
Abdominal
Pain
5 reported abdominal pain,
8 reported “stomachaches/pain”
Stomachaches or
bellyaches
All participants understood stomachaches and bellyaches. Even though
it is grammatically incorrect, patients preferred the separation of
stomach and belly to aches.
How often do you have stomach
aches or belly aches?
How bad are the stomach aches
or belly aches?
Dysphagia/
Food
Impaction
3 reported dysphagia,
16 described “trouble swallowing”
4 reported feeling of “food getting stuck
“
Trouble swallowing
Needing a drink to help
swallow food
Needing more time to eat
than other children the
same age.
Feeling like food gets
stuck in throat or chest
All participants understood trouble swallowing.
All participants understood needing a drink to help swallow food. Some
participants did not know that this was a symptom of EoE.
All participants understood needing more time to eat than other
children the same age. Some patients did not see this as a symptom of
EoE but as a behavioral issue.
The participants agreed that how bad did not apply to this question,
and there for only frequency was used
All participants understood feeling like food gets stuck in throat or chest
How bad is the trouble
swallowing?
How bad is the trouble
swallowing?
How often do you need to drink a
lot to help swallow your food?
How bad is it if you don’t drink a
lot to help swallow your food?
How often do you need more
time to eat than others?
Item deleted
How often do you feel like food
gets stuck in your throat or chest?
Vomiting 9 reported vomiting,
5 reported “throwing up”
Throwing up (vomiting) All participants understood throwing up How often do you vomit (throw
up)?
How bad is the vomiting
(throwing up)?
Nausea 2 reported nausea,
3 reported “feeling like they are
going to throw up but don’t”
Feeling like throwing up,
but didn’t (nausea)
38 out of 39 participants understood the term nausea. All participants
did understand the descriptive phrase for nausea.
How often do you feel nauseous
(feel like you’re going to throw
up, but don’t)?
How bad is the nausea (feeling
like you’re going to throw up, but
don’t)?
Regurgitation 6 described as “food coming up throat”. Food coming back up
throat when eating
All patients understood food coming back up throat when eating. How often does food come back
up your throat when eating?
How bad is the food coming back
up your throat when eating?
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2Table 4 Revised items and reasons for revision (Continued)
Poor
appetite
13 reported poor appetite or “not
wanting to eat”
Not eating as much as
other children the same
age
Most patients understood not eating as much as other children as a
measure for poor appetite and inadequate weight gain.
The participants agreed that how bad did not apply to this question,
and therefore, only frequency was used
How often do you eat less than
others?
Inadequate
weight gain
1 reported inadequate weight gain The 30 day time frame of PEESS v 2.0 does not allow for appropriate
measure of inadequate weight gain.
Item Deleted
Early Satiety 1 reported early satiety My child has/I have two or
more of these problems
this often:
Other problems. They are:
Removed because only one patient reported early satiety as a symptom.
All 39 subjects found this question confusing and unnecessary. It was
removed in the final version.
All 39 subjects found this question unnecessary as all symptoms
pertaining to EoE were covered. It was removed in the final version.
Item Deleted
Item Deleted
Item Deleted
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2questions raised about the language of the severity score
response choices, a combined pictorial scale and Likert
scale was presented to participants. The feedback regard-
ing this addition was uniformly positive, with participants
asserting that the draft was much easier to interpret. For
items such as vomiting, nausea, and heartburn, partici-
pants thought that having explanations of these terms in
parentheses allowed for easier comprehension.
Cognitive Interview Parent Proxy-Report
A separate cohort of parents of children ages 2-4, 5-7, 8-
12, and 13-18 was identified and interviewed indepen-
dently from their children. Overall, responses to the
PEESS™ version 2.0 preliminary draft were very positive,
with participants reporting the response choices as much
easier to understand than those in the PEESS v1.0. The
addition of several questions regarding dysphagia was also
positively received, and participants thought it was impor-
tant to include all additional questions. The items “eating
less food than others” and “needing more time to eat”
were particularly important to parents of children in the
2-4 and 5-7 year age groups. Questions were raised about
the overall layout of the instrument; many parents (as well
as patients) thought that having frequency and severity of
particular items side by side, rather than on two separate
pages, would facilitate measuring each symptom compre-
hensively (Figure 2).
Final Data Analysis and Construction of the PEESS™ v2.0
After the 39 cognitive interviews were concluded, each
interview transcript was reviewed in conjunction with
the 36 focus interview transcripts (75 total interviews).
Participants’ demographics are provided in Table 3.
R e s u l t sa r ei l l u s t r a t e di nF i g u r e2a n ds u m m a r i z e di n
Table 4. Saturation of themes and changes were deemed
achieved when no new themes emerged during the
focus interviews or suggestions for changes occurred
during the cognitive interviews. If two or more partici-
pants did not like a particular item or shared a particu-
lar concern, the item was reviewed and modified by the
research team. We modified additional language and
item constructs based on Flesch Reading Easiness and
Flesch-Kincaid Grade Level [17]. For example, items 5
and 6 were changed from the grammatically correct
“stomachaches” and “bellyaches” to the grammatically
incorrect “stomach aches” and “belly aches.” This adjust-
ment increased the Flesch Reading Ease score and
decreased the Flesch-Kincaid Grade level, suggesting
that the items were easier to comprehend. Disagree-
ments were resolved by discussion, and the PEESS™
v2.0 was developed. The metrics are shown in Addi-
tional Files 1 and 2, and are available at http://www.
mapi-trust.org.
Discussion
Pediatric patient self-reported and parent proxy-reported
outcomes are critical components of evaluating the
impact of current and planned treatments for pediatric
EoE. We report a patient self-report and parent-proxy
Pediatric EoE Symptom Score (PEESS™ v2.0) metric
with content-validation. The key distinction between the
PEESS v1.0 compared to the PEESS™ v2.0 is that the
former are physician developed metrics, while the latter
was developed from the words and descriptions of
patients and families following FDA guidelines published
in 2009.
The variety of symptoms reported by pediatric EoE
patients and their families in the development of the
PEESS™ v2.0 was surprising. The existing literature
reports that adult EoE patients often describe varying
degrees of dysphagia, whereas children often describe
pain without dysphagia as their only symptom [1,3].
Characterization of dysphagia from multiple perspectives
was critical to capturing this important symptom.
Patients and parent proxies were often aware that they
(or their child) were experiencing dysphagia as assessed
by items such as “trouble swallowing” or “food getting
stuck while eating.” However, the addition of items
including “t a k i n gal o n gt i m et oe a tf o o d ” and “needing
to drink a lot of water while eating food” captured the
more subtle descriptions of dysphagia. Utilizing two dis-
tinct cohorts for the focus interviews and cognitive
interviews also yielded invaluable information and
allowed further refinement of patient self-reported and
parent proxy-reported perspectives, achieving content
saturation. In particular, clarification and increased read-
ing ease of directions, addition of a combined pictorial
scale and Likert scale, language modification, and
changes in instrument layout were all developed from
the cognitive interviews.
One particular concern regarding parent-proxy
reported outcomes is that they may not be acceptable to
the current FDA guidelines regarding product labeling
specifications. For FDA-endorsed clinical trials that
would use the PEESS™ v2.0, it may be that presently we
are only able to obtain specific PRO based labeling for
pediatric self-report ages 8-18 years of age. Current opi-
nion at the FDA is that parent observer tools for children
2-7 years of age are recommended to include only symp-
toms clearly observable by the parent, such as: vomiting,
increased time needed to eat, and drinking a large
amount of liquids to swallow food. Therefore, only a sub-
scale of questions may able to be used for clinical trials in
children 2-7 years of age. However, it is also vital to
recognize that FDA opinion for labeling purposes regard-
ing PROs has changed significantly in the past several
decades. It is highly possible that the current thinking on
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Page 8 of 12parent-proxy metrics (widely supported by many psycho-
metricians and clinicians alike) may also change. In
future studies, we will be conducting responsiveness test-
ing of the PEESS™ v2.0 metric, further assessing the
parent proxy-report metric and specific subscales. Finally,
the PEESS™ v2.0 is intended for use both in and outside
of the clinical trial setting. We felt that all of the symp-
toms important to patients and their parents as proxy are
Focus Interview developed  
          PEESS v 2.0 
  
PEESS™ v 2.0 draft 2 
 
                     
 
    
  
                   
PEESS™ v 2.0 draft 1 
Physician developed    
PEESS v 1.0 
Validated PEESS™ v 2.0 
Figure 2 From the PEESS v1.0 to the validated PEESS™ v 2.0. The instrument layout and overall design went through several iterative drafts
based on patient and parent-proxy feedback through focus interviews and separate cognitive interviews. For example, participants favored
presenting frequency and severity of particular items side by side rather than on two separate pages.
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picture of symptomatology.
In developing a metric for pediatric EoE, it is important
to ensure that all patient areas of concern are fully elicited
- a concept often termed item saturation, and a key reason
why we performed our 75 patient and parent proxy inter-
views in two stages and two separate cohorts. Item satura-
tion was achieved for each question and questionnaire as a
whole during the cognitive interviews for each age range.
Specific questions are provided in Table 2, including: “how
would you change the questions words to make it easier to
understand” and the overall assessment question “are
there things that we forgot to ask about that you feel are
important?” These questions were asked to the patients in
the 8-18 year old age ranges and to the parents in the 2-18
year old age ranges. In response, the landscape question-
naire format and front page directions were changed early
on, and the final draft was reviewed by patients in this
format. This is an important distinction from the Flood
etal. metric and the PEESS v1.0 in that items were gener-
ated by the patients in one cohort and then reviewed by a
second cohort. However, the item content if the PEESS™
v2.0 is supported by the symptom overlap reported by
Flood et al. and other investigators [3,15,18].
Another controversial area in PRO development is
recall period. Some may argue that a one month recall
period for the PEESS™ v2.0 is too long to accurately
assess change. The use of a one month recall period has
been well described by Varni and colleagues [19-26]. In
addition, the Mayo Dysphagia Questionnaire developed
by Romero and colleagues was shown not to be respon-
sive over a 14 day recall period, but responsive over a 30
day (1 month) recall period [27]. In future studies we will
be conducting responsiveness testing of the PEESS™
v2.0 metric and will be assessing different recall periods -
1 week, 2 week and 1 month. One alternative to improve
patient accuracy in symptom reporting by a shorter recall
period and also allow for a total responsive period of 30
days would be to collect symptom scores on a weekly
basis for 4 weeks, and then report a 30 day summation
score. Some have also advocated for the use of daily
assessments through electronic diaries. We considered
using daily electronic diaries, but we have found the
patient response-burden too high, and that these diaries
are impractical for any but the most highly funded and
closely regulated clinical trials. The PEESS™ v2.0 is
intended for use both in and outside the clinical trial set-
ting as a simple, yet effective patient-derived metric that
does not cause undue burden on patients, families, clini-
cians, or researchers.
There are several important limitations to this study.
Although the PEESS™ v2.0 metric represents an impor-
tant step forward for the field of pediatric EoE, further
testing and modifications will be needed. Despite item
saturation, there may be additional EoE symptoms that
have not been included. In addition, generalizability to
non-Caucasians and to patients with co-morbidities may
be a potential concern. For the PEESS™ v2.0 metric
development and cognitive interviews, we felt it critical
to assess patients’ and families’ concerns specific to EoE,
not those related to other co-morbidities. In the next
phase of the PEESS™ v2.0 metric development, we will
test the metric construct and reliability in over 200
patients and 250 parents across a variety of demo-
graphics and co-morbidities. The fourth phase of psy-
chometric testing will test the responsiveness of the
PEESS™ v2.0 metric, key to assessing the potential per-
formance of the PEESS™ v2.0 in clinical trials. The
PEESS™ v2.0 metrics are available at http://www.mapi-
trust.org.
Conclusions
Currently, pediatric EoE is assessed using number of
eosinophils per high powered field in an esophageal
endoscopic biopsy specimen as the primary outcome
variable. Symptoms are at best reported as secondary
outcomes utilizing physician directed questions, without
any attention to PROs [2,28]. It is currently well-
described that the severity of histologic inflammation in
EoE as measured by tissue eosinophil counts may not
directly relate to the degree of symptom severity [5]. For
example, initial data in the pediatric Reslizumab (Cin-
quil
®) study suggests that patient symptoms and health
related quality of life (HRQOL) do not correlate with
histologic esophageal inflammation [29]. In a condition
without known risk of malignancy or reduced life expec-
tancy, PROs need to be equally if not more important
outcome measures compared to histologic disease activ-
ity. Face and content validation of the PEESS™ v2.0 are
important first steps to establishing patient self-report
and parent proxy-report symptom assessments as key
factors in pediatric EoE for patients, families, research-
ers, and care providers alike.
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